Beijing Chemclin Biotech Co. completed a $16.5 million Series B round that it will use to further its diagnostics reagents business. The financing was led by a new investor, China Healthcare Partnership (managed by MC China), and it included existing investors, WI Harper, Siemens Venture Capital, and SB China Venture Capital. The investment bank China eCapital advised Chemclin in the transaction. Formed in 1999, Chemclin markets radioimmunoassay (RIA) kits, ELISA and chemiluminescent (CLIA) reagents. More details...